» Articles » PMID: 37681919

MT1-MMP As a Key Regulator of Metastasis

Overview
Journal Cells
Publisher MDPI
Date 2023 Sep 8
PMID 37681919
Authors
Affiliations
Soon will be listed here.
Abstract

Membrane type1-matrix metalloproteinase (MT1-MMP) is a member of metalloproteinases that is tethered to the transmembrane. Its major function in cancer progression is to directly degrade the extracellular matrix components, which are mainly type I-III collagen or indirectly type IV collagen through the activation of MMP-2 with a cooperative function of the tissue inhibitor of metalloproteinase-2 (TIMP-2). MT1-MMP is expressed as an inactive form (zymogen) within the endoplasmic reticulum (ER) and receives truncation processing via furin for its activation. Upon the appropriate trafficking of MT1-MMP from the ER, the Golgi apparatus to the cell surface membrane, MT1-MMP exhibits proteolytic activities to the surrounding molecules such as extracellular matrix components and cell surface molecules. MT1-MMP also retains a non-proteolytic ability to activate hypoxia-inducible factor 1 alpha (HIF-1A) via factors inhibiting the HIF-1 (FIH-1)-Mint3-HIF-1 axis, resulting in the upregulation of glucose metabolism and oxygen-independent ATP production. Through various functions of MT1-MMP, cancer cells gain motility on migration/invasion, thus causing metastasis. Despite the long-time efforts spent on the development of MT1-MMP interventions, none have been accomplished yet due to the side effects caused by off-target effects. Recently, MT1-MMP-specific small molecule inhibitors or an antibody have been reported and these inhibitors could potentially be novel agents for cancer treatment.

Citing Articles

A prognostic model for lung adenocarcinoma based on cuproptosis and disulfidptosis related genes revealing the key prognostic role of FURIN.

You J, Yu Q, Chen R, Li J, Zhao T, Lu Z Sci Rep. 2025; 15(1):6057.

PMID: 39972012 PMC: 11840156. DOI: 10.1038/s41598-025-90653-5.


Assessment of Protein Immunoexpression Associated with Tumor Proliferation and Invasion in Histological Subtypes of Unicystic and Conventional Ameloblastoma.

da Silveira G, Costa R, Lemos F, de Moraes A, da Silva Kataoka M, Freitas V Int J Mol Sci. 2025; 26(3).

PMID: 39941035 PMC: 11818812. DOI: 10.3390/ijms26031267.


The Diverse Pathways for Cell Surface MT1-MMP Localization in Migratory Cells.

Kelly H, Inada M, Itoh Y Cells. 2025; 14(3).

PMID: 39937000 PMC: 11816416. DOI: 10.3390/cells14030209.


Exploring the Chemical Features and Biomedical Relevance of Cell-Penetrating Peptides.

Moreno-Vargas L, Prada-Gracia D Int J Mol Sci. 2025; 26(1.

PMID: 39795918 PMC: 11720145. DOI: 10.3390/ijms26010059.


Cancer-Targeting Applications of Cell-Penetrating Peptides.

Moreno-Vargas L, Prada-Gracia D Int J Mol Sci. 2025; 26(1.

PMID: 39795861 PMC: 11720565. DOI: 10.3390/ijms26010002.


References
1.
Chamberland J, Ritter B . Retromer revisited: Evolving roles for retromer in endosomal sorting. J Cell Biol. 2017; 216(11):3433-3436. PMC: 5674901. DOI: 10.1083/jcb.201708111. View

2.
Kasurinen A, Gramolelli S, Hagstrom J, Laitinen A, Kokkola A, Miki Y . High tissue MMP14 expression predicts worse survival in gastric cancer, particularly with a low PROX1. Cancer Med. 2019; 8(16):6995-7005. PMC: 6853825. DOI: 10.1002/cam4.2576. View

3.
Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H . Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol. 2001; 153(5):893-904. PMC: 2174329. DOI: 10.1083/jcb.153.5.893. View

4.
Brookes M, Roundhill E, Jeys L, Parry M, Burchill S, Rankin K . Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma. Pediatr Blood Cancer. 2022; 69(12):e29959. DOI: 10.1002/pbc.29959. View

5.
Lohi J, Lehti K, Valtanen H, Parks W, Keski-Oja J . Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene. 2000; 242(1-2):75-86. DOI: 10.1016/s0378-1119(99)00549-1. View